ONO PHARMACEUTI/ADR (OTCMKTS:OPHLY) Cut to “Neutral” at Morgan Stanley
Morgan Stanley downgraded shares of ONO PHARMACEUTI/ADR (OTCMKTS:OPHLY) from an overweight rating to a neutral rating in a report published on Thursday, The Fly reports.
Separately, JPMorgan Chase & Co. downgraded shares of ONO PHARMACEUTI/ADR from an overweight rating to a neutral rating in a report on Tuesday, March 5th.
Shares of OTCMKTS OPHLY opened at $5.94 on Thursday. ONO PHARMACEUTI/ADR has a twelve month low of $5.60 and a twelve month high of $10.50.
Ono Pharmaceutical Co, Ltd. produces and sells pharmaceuticals and diagnostic reagents worldwide. Its products include OPDIVO intravenous infusions for the treatment of malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; GLACTIV and FORXIGA tablets for type 2 diabetes; KINEDAK tablets to treat diabetic peripheral neuropathy; PARSABIV, an intravenous injection for dialysis patients; RECALBON tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONOACT injections for treating tachyarrhythmia; Staybla tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and Foipan tablets to treat chronic pancreatitis and postoperative reflux esophagitis.
See Also: Cost of Equity
Receive News & Ratings for ONO PHARMACEUTI/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ONO PHARMACEUTI/ADR and related companies with MarketBeat.com's FREE daily email newsletter.